Tarsus Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-09-01

Reporting Person: Ackermann Michael (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-01	Common Stock	S	5833	$25.242	Disposed	1221515	Direct

Footnotes

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2021.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices with the range of $25.000 to $25.970, inclusive. The Reporting Person undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.